Cerebral venous thrombosis (CVT) is a rare thrombotic disorder involving the cerebral veins
and dural sinuses. In contrast to more common sites of venous thromboembolism (VTE) …

Use of oral contraceptives (OC) that combine a progestogen with synthetic ethinyl estradiol
(EE) is associated with increased risk of venous thromboembolism. NOMAC/E2 is a new …

Objective A systematic review of studies published between January 1995 and April 2010
aimed at determining the effect of combined hormonal contraceptives (CHCs), administered …

Objective—The beneficial effect of dietary fish oil, rich in omega-3 polyunsaturated fatty
acids (PUFAs), on cardiovascular disease is multifactorial and may partly rely on their …

The incidence of venous thrombosis is 1–3 individuals per 1000 per year, with a high rate of
complications and death. Men and women are affected about equally by venous thrombosis …

Activated protein C (APC) resistance, determined with a thrombin‐generation‐based APC
resistance test, may explain risk differences of venous thrombosis in users of second‐and …

Background: It takes many years to obtain reliable values for the risk of venous thrombosis of
hormonal contraceptive users from clinical data. Measurement of activated protein C (APC) …

Focusing on a lucrative and increasingly important area of biomedicine, the Biomaterials
Fabrication and Processing Handbook brings together various biomaterials production and …

Oral contraceptives and hormone replacement therapy are used by hundreds of millions of
women worldwide. Since the early 1960s it is known that female hormones increase the risk …

This is the first double-blind, controlled, randomized study comparing the effect of different
estrogen components in oral contraceptives (OCs) on hemostasis variables. Four groups of …